Key result
Riociguat improves cardiopulmonary hemodynamics in early-phase studies of patients with pulmonary hypertension.
Why the study?
The prognosis for patients with pulmonary hypertension remains poor despite recent treatment advances, creating a need for therapies with new modes of action.
Does riociguat improve cardiopulmonary haemodynamics in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension?
Does riociguat improve cardiopulmonary haemodynamics in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension?
Riociguat is an emerging oral soluble guanylate cyclase stimulator that improves cardiopulmonary hemodynamics in pulmonary hypertension, supporting further phase-III investigation.
No takes yet. Share an insight, caveat, or question.
Should not yet change practice in pulmonary hypertension; leaves open confirmation of riociguat benefits in phase 3 trials.
Ghofrani et al. (2009) conducted a review in pulmonary hypertension. Riociguat was evaluated. Riociguat, an oral stimulator of soluble guanylate cyclase, improved cardiopulmonary hemodynamics from baseline in early-phase studies of patients with pulmonary hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: